Advertisement

Topics

Cedilla Therapeutics Company Profile

10:03 EDT 27th May 2018 | BioPortfolio


News Articles [771 Associated News Articles listed on BioPortfolio]

Cedilla Therapeutics Launches with $56.2 Million

Cedilla Therapeutics, headquartered in Cambridge, Massachusetts, launched with a $56.2 million Series A round from Third Rock Ventures.

Third Rock Ventures Launches Cedilla Therapeutics to Target Protein Stability Using Small Molecule Therapeutics

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cedilla Therapeutics, a new biotechnology company broadening the reach of small molecule therapeutics by discovering and exploiting unique insights into pr...

Cedilla Therapeutics launches with $56mm Series A

Cedilla Therapeutics (proteomics-based drug discovery) launched with $56mm in Series A funding from Third Rock Ventures.

Deals this week: EryDel SPA, Cedilla Therapeutics, Sangamo

Italian biotech company EryDel SPA has raised €6.5m ($32.4m) through venture financing in order to enhance its international development and...Read More... The post Deals this week: EryDel SPA, Cedi...

Protein stability play Cedilla launches with $56.2M series A

Third Rock Ventures Launches Cedilla Therapeutics with $56 Million Investment to Target Protein Stability Using Small Molecule Therapeutics

Company is targeting upstream aspects of native protein degradation pathways to develop new therapies for cancer Cedilla Therapeutics, a new biotechnology company broadening t...

Protein player

Third Rock-backed Cedilla will deploy $56 million to develop small molecules that stabilize or degrade target proteins.

Global Veterinary Therapeutics Market to Mark CAGR of 6.0% Over Next 10 Years - MarketResearch.biz

MarketResearch.biz announces publication of its recently generated research report titled, "GlobalVeterinary Therapeutics MarketBy Type (Therapeutics Drugs, Therapeutics Vaccines, Feed Additives The...

PubMed Articles [393 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Introduction to Volume 1 of JOPT Special Issue.

Introduction to Volume 2 of JOPT Special Issue.

Clinical Trials [142 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1232 Associated Companies listed on BioPortfolio]

Cedilla Therapeutics

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "Cedilla Therapeutics" on BioPortfolio

We have published hundreds of Cedilla Therapeutics news stories on BioPortfolio along with dozens of Cedilla Therapeutics Clinical Trials and PubMed Articles about Cedilla Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cedilla Therapeutics Companies in our database. You can also find out about relevant Cedilla Therapeutics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record